Dianthus Therapeutics (DNTH) and partner Nanjing Leads Biolabs said Tuesday the first subject was dosed in a phase 1 clinical trial of the LBL-047 bifunctional fusion protein developed by Nanjing.

The two-part, dose-escalation trial will assess the safety, tolerability and pharmacokinetics/pharmacodynamics of LBL-047 in healthy volunteers and patients with systemic lupus erythematosus.

The companies expect to report top-line results in healthy volunteers in H2 of 2026, while Dianthus plans to provide an update on indication prioritization in H1.

Systemic lupus erythematosus is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body.

Dianthus shares were up 2.1% in recent premarket activity.